Fresenius SE & Co. KGaA

History

Year	Detail
1912	The pharmacist, Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company, Dr. E. Fresenius.
1966	Fresenius started selling its dialysis machines and dialyzers manufactured by various foreign companies and gained substantial market shares.
1974	Fresenius begins manufacturing infusion solutions and medical disposables in St. Wendel, in Germany's Saarland region.
1979	The company started producing the A2008 dialysis machine in its newly acquired factory in Schweinfurt. The machine was awarded a gold medal at the Leipzig Trade Fair that year.
1983	Fresenius started the production of synthetic polysulfone fiber membranes for blood purification.
1994	With the acquisition of Hospitalia International, Fresenius entered the project business to develop hospitals and other healthcare facilities.
1996	The company's dialysis business merged with National Medical Care, the U.S. dialysis provider, creating Fresenius Medical Care, the world's leading dialysis provider.
1999	After acquiring Pharmacia & Upjohn's international nutrition business, Fresenius merged with Fresenius Pharma to form Fresenius Kabi.
2001	Fresenius acquired Wittgensteiner Kliniken AG, one of Germany's major global operators of private hospitals.
2005	Fresenius acquired Helios Kliniken GmbH, one of Germany's top three private hospital operators. This acquisition provides Fresenius an excellent platform for further growth in the German acute care market.
2006	Fresenius Medical Care acquired Renal Care Group, a U.S. dialysis care provider. Through its network of approximately 2,000 dialysis clinics worldwide, Fresenius Medical Care will deliver dialysis treatment to around 157,000 patients.
2008	Fresenius Kabi strengthens its business with intravenously administered generic drugs (I.V. generics) and expands into oncology drugs by acquiring the Indian company Dabur Pharma.
2021	Fresenius Helios acquired Eugin Group, a leading international group in fertility treatments, and entered the reproductive medicine segment.